Clinical Trials & Surveys Corp. (C-TASC), a clinical trials solutions company, announced today that it has been selected to provide data management software and services to New York University School of Medicine (NYU), one of eight sites collecting data for a study being conducted by the Early Detection Research Network.
NEW YORK UNIVERSITY TAPS C-TASC FOR
CLINICAL STUDY DATA MANAGEMENT
Early Detection Research Network Study Aims to Improve
Early Diagnosis of Lung Cancer
Baltimore, Md. – (December 8, 2008)-Clinical Trials & Surveys Corp. (C-TASC), a clinical trials solutions company, announced today that it has been selected to provide data management software and services to New York University School of Medicine (NYU), one of eight sites collecting data for a study being conducted by the Early Detection Research Network. The purpose of the study is to identify biomarkers to serve as early detectors of lung cancer.
Under the three year contract, C-TASC will implement its StudyCTMSTM clinical trials management software solution to manage all EDRN study data collected and maintained at the New York University site. The software will be utilized to convert tens of thousands of existing data records into one universal format. Housing the data in a single format will make the accumulated results easier to read, compile, analyze and prepare for submission upon completion of the study. StudyCTMSTM will also be used for the collection and validation of all enrollment, follow up and specimen data for the 1,100 current study participants as well as all future participants.
C-TASC’s new Bio Repository Management System (BRMS), a fully integrated module of StudyCTMSTM, will also be deployed at NYU, enabling investigators to easily manage the processing, delivery, archival and allocation of all EDRN laboratory research specimens catalogued at the study site.
StudyCTMSTM is C-TASC’s proprietary Web-based data management solution that enables investigators to easily develop and manage clinical studies and deliver the accumulated data and metadata (labels, value labels, etc.) in an easy-to-read and FDA-acceptable format.
“C-TASC’s implementation of StudyCTMSTM at NYU is significant because it marks our first private software lease to a non-government supported researcher,” said Bruce Thompson, president of C-TASC. “Working with the EDRN will allow us to fine-tune the program’s array of features to ensure that we are providing clinical investigators with the optimum user experience to support their clinical trial work.”
About C-TASC
Based in Baltimore, Maryland, Clinical Trials & Surveys Corp. (C-TASC) is a clinical trials solutions company that supports best practices management of clinical trials, clinical cohort studies, case/control studies, clinical registries and laboratory studies. Founded in 1989, C-TASC provides clients with complete research management including medical and statistical study design, project management, performance monitoring and data quality control and analysis as well as support for study publication and presentations. C-TASC’s professional services group has a successful research history in cancer, cardiovascular disease, AIDS, pulmonary disease, Cystic Fibrosis, pharmaco-epidemiology and bio-repository establishment and coordination. For more information about C-TASC’s projects, products and services, please visit www.c-tasc.com <http://www.c-tasc.com/> .
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.